Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bt8009 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Bicycle Therapeutics
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BT8009 + pembrolizumab is an **investigational combination therapy** for cancer, currently being evaluated primarily in locally advanced or metastatic urothelial cancer. **BT8009 (zelenectide pevedotin)** is a **Bicycle drug conjugate** (BDC), consisting of a highly selective bicyclic peptide that targets **nectin-4**—a cell adhesion molecule commonly overexpressed on tumor cells—conjugated to the cytotoxin **monomethyl auristatin E (MMAE)** by a cleavable linker. BT8009 rapidly penetrates solid tumors and is designed for rapid systemic clearance, potentially minimizing toxicity to normal tissue. **Pembrolizumab** is a humanized monoclonal antibody that inhibits **programmed cell death protein 1 (PD-1)**, thereby preventing tumor cells from evading immune detection and supporting immune-mediated tumor cell killing. The combination is being studied versus standard chemotherapy regimens to explore if the synergistic anti-cancer effects can improve progression-free survival and response rates in urothelial carcinoma and potentially other advanced solid tumors[1][3][4][5][6][7][8].
- Brand names
- zelenectide pevedotin + pembrolizumab
- Other names
- zelenectide pevedotin + pembrolizumab
02
Targets
TUBB (Tubulin (alpha and beta subunits))PVRL4 (Nectin cell adhesion molecule 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on bt8009 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bt8009 + pembrolizumab.